To assist preclinical research of RNA drugs, Medicilon and Acon Pharmaceuticals reached a strategic collaboration

On June 24, 2022, Shanghai Medicilon Inc. (Medicilon) and ACON Pharmaceuticals Inc. (ACON) reached a strategic collaboration.  The two parties have reached a consensus on specific collaboration matters in the preclinical research and development of RNA drugs, and will carry out in-depth collaboration.

In order to promote the preclinical research and development of RNA drugs more efficiently and with high quality, ACON and Medicilon have formed a strong strategic alliance, and have reached a total of 4 siRNA and 1 mRNA drug pharmaceutical research and IND filing for preclinical studies.  According to the agreement, the two parties will give full play to the superior resources and professional capabilities of the Medicilon’s nucleic acid drug development platform and the dual-engine drug development platform of ACON's RNA drug design and drug delivery system.  This could reduce the R&D cost of new RNA drugs, accelerate the R&D process, and provide patients with high-quality and affordable treatment options.

Acon Pharmaceuticals Inc. is a specialty pharmaceutical company and focuses on siRNA and mRNA drug delivery, 505(b)(2) NDA, and complex ANDA drug product development with its captive drug delivery system technology platforms. Acon Pharma is a privately held corporation located in Princeton, New Jersey, USA. As a dynamic pharmaceutical company in a vibrant life science research region, Acon Pharma leverages the expertise and experience of highly skilled, multi-disciplinary workforce to accelerate the product development of complex drug delivery systems. The Company’s key managers were primarily educated in US with advanced degrees and trained in the pharmaceutical industry for many years, and have possessed deep professional knowledge, technical know-how, and extensive experiences in pharmaceutical product development.

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of 2021, Medicilon has provided new drug R&D services to more than 1,460 clients around the world, and participated in the R&D of 221 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.